NT5E and exocrine pancreatic carcinoma: Preliminary results from early phase trials have shown clinical efficacy for the therapeutic inhibition of CD73 by monoclonal antibodies such as oleclumab with or without the PD-L1 inhibitor durvalumab and led to PRs in heavily pretreated patients with colorectal or pancreatic carcinomas (Overman et al. 2018; Caluwe et al. 2021).